Armistice Capital, LLC Madrigal Pharmaceuticals, Inc. Transaction History

Armistice Capital, LLC

$7.34 Billion
Q1 2024

A detailed history of Armistice Capital, LLC transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Armistice Capital, LLC holds 168,000 shares of MDGL stock, worth $47.1 Million. This represents 0.61% of its overall portfolio holdings.

Number of Shares

168,000

Previous 50,000 236.0%

Holding current value

$47.1 Million

Previous $11.6 Million 287.78%

% of portfolio

0.61%

Previous 0.16%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$171.37 - $283.23 $20.2 Million - $33.4 Million	118,000 Added 236.0%	168,000 $44.9 Million
Q4 2023 Feb 13, 2024	SELL	$120.4 - $237.13 $6.98 Million - $13.8 Million	-58,000 Reduced 53.7%	50,000 $11.6 Million
Q3 2023 Nov 14, 2023	SELL	$146.04 - $225.78 $4.09 Million - $6.32 Million	-28,000 Reduced 20.59%	108,000 $15.8 Million
Q2 2023 Aug 14, 2023	SELL	$203.88 - $312.0 $28.5 Million - $43.7 Million	-140,000 Reduced 50.72%	136,000 $31.4 Million
Q1 2023 May 15, 2023	BUY	$231.06 - $307.08 $15.7 Million - $20.9 Million	68,000 Added 32.69%	276,000 $66.9 Million

Q4 2022 Feb 14, 2023	SELL	$58.39 - $296.54 $60 Million - $305 Million	-1,028,000 Reduced 83.17%	208,000 $60.4 Million
Q3 2022 Nov 14, 2022	BUY	$60.57 - $79.51 $8.24 Million - $10.8 Million	136,000 Added 12.36%	1,236,000 $80.3 Million
Q2 2022 Aug 15, 2022	BUY	$58.04 - $100.2 $7.08 Million - $12.2 Million	122,000 Added 12.47%	1,100,000 $78.7 Million
Q1 2022 May 16, 2022	SELL	$55.89 - $101.89 $8.16 Million - $14.9 Million	-146,000 Reduced 12.99%	978,000 $96 Million
Q4 2021 Feb 14, 2022	BUY	$72.34 - $95.09 $6.37 Million - $8.37 Million	88,000 Added 8.49%	1,124,000 $95.2 Million
Q3 2021 Nov 15, 2021	BUY	$78.35 - $105.02 $34.8 Million - $46.6 Million	444,000 Added 75.0%	1,036,000 $82.7 Million
Q2 2021 Aug 16, 2021	BUY	$97.2 - $137.59 $23.5 Million - $33.3 Million	242,000 Added 69.14%	592,000 $57.7 Million
Q1 2021 May 17, 2021	BUY	$108.54 - $125.2 $3.69 Million - $4.26 Million	34,000 Added 10.76%	350,000 $40.9 Million
Q4 2020 Feb 16, 2021	BUY	$110.06 - $133.7 $4.18 Million - $5.08 Million	38,000 Added 13.67%	316,000 $35.1 Million
Q3 2020 Nov 16, 2020	BUY	$99.78 - $124.21 $2.99 Million - $3.73 Million	30,000 Added 12.1%	278,000 $33 Million
Q2 2020 Aug 14, 2020	BUY	$60.13 - $125.71 $1.92 Million - $4.02 Million	32,000 Added 14.81%	248,000 $28.1 Million
Q1 2020 May 15, 2020	BUY	$66.76 - $93.49 $3.74 Million - $5.24 Million	56,000 Added 35.0%	216,000 $14.4 Million
Q4 2019 Feb 14, 2020	BUY	$84.28 - $118.5 $4.38 Million - $6.16 Million	52,000 Added 48.15%	160,000 $14.6 Million
Q3 2019 Nov 14, 2019	SELL	$84.4 - $106.53 $25.3 Million - $32 Million	-300,000 Reduced 73.53%	108,000 $9.31 Million
Q2 2019 Aug 14, 2019	SELL	$91.13 - $142.5 $1.55 Million - $2.42 Million	-17,000 Reduced 4.0%	408,000 $42.8 Million
Q1 2019 May 15, 2019	BUY	$103.48 - $143.84 $44 Million - $61.1 Million	425,000 New	425,000 $53.2 Million
Q4 2018 Feb 14, 2019	SELL	$94.77 - $215.54 $7.58 Million - $17.2 Million	-80,000 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$207.3 - $300.31 $16.6 Million - $24 Million	80,000 New	80,000 $17.1 Million
Q2 2018 Aug 14, 2018	SELL	$101.55 - $313.9 $10.4 Million - $32 Million	-102,000 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$93.35 - $149.04 $3.92 Million - $6.26 Million	42,000 Added 70.0%	102,000 $11.9 Million
Q4 2017 Feb 14, 2018	SELL	$39.35 - $97.37 $5.98 Million - $14.8 Million	-152,000 Reduced 71.7%	60,000 $5.51 Million
Q3 2017 Nov 14, 2017	BUY	$15.48 - $46.19 $3.28 Million - $9.79 Million	212,000	212,000 $9.54 Million

Others Institutions Holding MDGL

# of Institutions

313

Shares Held

20M

Call Options Held

824K

Put Options Held

1.04M

View Full List

About MADRIGAL PHARMACEUTICALS, INC.

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $4.79B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

More about MDGL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Armistice Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Armistice Capital, LLC with notifications on news.

Account

Armistice Capital, LLC Madrigal Pharmaceuticals, Inc. Transaction History